ClinicalTrials.gov
ClinicalTrials.gov Menu

ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00993642
Recruitment Status : Withdrawn (Lack of accrual)
First Posted : October 12, 2009
Last Update Posted : March 13, 2017
Sponsor:
Collaborators:
Novartis
Board of Regents, State of Louisiana
Information provided by (Responsible Party):
Bridgette Collins-Burow, Tulane University

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Recruitment Status : Withdrawn
  Actual Primary Completion Date : September 2010
  Actual Study Completion Date : December 2010